Last reviewed · How we verify
NCT06935136
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
NA trial testing Axicabtagene Ciloleucel in CAR-T Cell Therapy in 60 participants. Not yet recruiting.
9 October 2026
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 30 April 2025 |
| Primary completion | 9 October 2026 |
| Estimated completion | 9 April 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Axicabtagene Ciloleucel — full drug profile →
Conditions studied
- CAR-T Cell Therapy — all drugs for CAR-T Cell Therapy →
- High-risk Large B-cell Lymphoma (LBCL) — all drugs for High-risk Large B-cell Lymphoma (LBCL) →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with CAR-T Cell Therapy or High-risk Large B-cell Lymphoma (LBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06935136
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Axicabtagene Ciloleucel
Trials testing the same drug.
- NCT07042438 — Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo · Phase 2 · recruiting
- NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
- NCT05077527 — Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
- NCT06826118 — Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma · Phase 2 · recruiting
- NCT07254754 — Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma · Phase 2 · recruiting
Other recruiting trials for CAR-T Cell Therapy
Currently open trials in the same condition.
- NCT07246304 — TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC · EARLY_PHASE1 · recruiting
- NCT07269587 — A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 · active not recruiting
- NCT07198867 — A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT07120633 — Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL · NA · recruiting
- NCT06842589 — Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS · Phase 1 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06935136 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06935136.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing